At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02142 HBM HOLDINGS-B
Market Closed 09-04 16:08:03
14.720
-0.380
-2.52%
High15.180Low14.390Vol7.28M
Open15.100D1 Closing15.100Amplitude5.23%
Mkt Cap12.79BTradable Cap12.79BTotal Shares869.00M
T/O108.66MT/O Rate0.84%Tradable Shares869.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜HBM HOLDINGS-B Rises 5.21% in Regular Trading, H1 Revenue Up Over 20% with Hang Seng Composite Index Inclusion Imminent
Market Focus  ·  09-03 14:51
Movement Alert｜HBM HOLDINGS-B Rises 5.21% in Regular Trading, H1 Revenue Up Over 20% with Hang Seng Composite Index Inclusion Imminent
HBM Holdings Clarifies Reasons Behind Executive Director's Departure
Deep News  ·  09-02 22:41
HBM Holdings Clarifies Reasons Behind Executive Director's Departure
HBM Holdings Says Dr. Yiping Rong Resigns as Executive Director to Focus on Other Commitments
Reuters  ·  09-02 16:33
HBM Holdings Says Dr. Yiping Rong Resigns as Executive Director to Focus on Other Commitments
Movement Alert｜HBM HOLDINGS-B Rises 5.37% in Regular Trading, Rebound Ahead of Hang Seng Composite Index Inclusion
Market Focus  ·  09-02 14:36
Movement Alert｜HBM HOLDINGS-B Rises 5.37% in Regular Trading, Rebound Ahead of Hang Seng Composite Index Inclusion
Movement Alert｜HBM HOLDINGS-B Falls 5.1% in Regular Trading, Revenue-Profit Divergence in Interim Results Continues to Weigh on Shares
Market Focus  ·  09-01
Movement Alert｜HBM HOLDINGS-B Falls 5.1% in Regular Trading, Revenue-Profit Divergence in Interim Results Continues to Weigh on Shares
Movement Alert｜HBM HOLDINGS-B Falls 5.24% in Regular Trading, Continued Selling Pressure as H1 Profit Declined 11% Despite Revenue Growth
Market Focus  ·  08-31
Movement Alert｜HBM HOLDINGS-B Falls 5.24% in Regular Trading, Continued Selling Pressure as H1 Profit Declined 11% Despite Revenue Growth
Movement Alert｜HBM HOLDINGS-B Drops 5.03% in Regular Trading, H1 Net Profit Declines 11% Despite Revenue Growth
Market Focus  ·  08-28
Movement Alert｜HBM HOLDINGS-B Drops 5.03% in Regular Trading, H1 Net Profit Declines 11% Despite Revenue Growth
HBM Holdings Appoints Youchen Chen and Ian Yi Liu as Executive Directors
Reuters  ·  08-27
HBM Holdings Appoints Youchen Chen and Ian Yi Liu as Executive Directors
HBM Holdings Delivers H1-2026 Revenue Growth to USD 122.49 Million While Net Profit Eases to USD 64.85 Million
Bulletin Express  ·  08-27
HBM Holdings Delivers H1-2026 Revenue Growth to USD 122.49 Million While Net Profit Eases to USD 64.85 Million
HBM Holdings Restructures Board: Dr. Yiping Rong Steps Down, Mr. Youchen Chen and Dr. Ian Yi Liu Join as Executive Directors
Bulletin Express  ·  08-27
HBM Holdings Restructures Board: Dr. Yiping Rong Steps Down, Mr. Youchen Chen and Dr. Ian Yi Liu Join as Executive Directors
HBM Holdings Files List of Directors, Board Committee Memberships and Disclosure-Responsible Management
Reuters  ·  08-27
HBM Holdings Files List of Directors, Board Committee Memberships and Disclosure-Responsible Management
HBM Holdings-B (02142) Posts First-Half Profit of $64.85M, Down 11.16% Year-on-Year
Stock News  ·  08-27
HBM Holdings-B (02142) Posts First-Half Profit of $64.85M, Down 11.16% Year-on-Year
China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs
Reuters  ·  08-27
China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs
Press Release: Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
Dow Jones  ·  08-27
Press Release: Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
HBM Holdings Names CFO Youchen Chen Executive Director Amid Board Changes
Reuters  ·  08-27
HBM Holdings Names CFO Youchen Chen Executive Director Amid Board Changes
Hbm Holdings - Yiping Rong Resigns as Executive Director Effective August 27, 2026
THOMSON REUTERS  ·  08-27
Hbm Holdings - Yiping Rong Resigns as Executive Director Effective August 27, 2026
Harbour Biomed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
THOMSON REUTERS  ·  08-27
Harbour Biomed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
Dow Jones  ·  08-27
Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million
Reuters  ·  08-27
HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million
Hbm Holdings H1 Revenue USD 122.5 Million
THOMSON REUTERS  ·  08-27
Hbm Holdings H1 Revenue USD 122.5 Million
No data available

Introduction

Company Name.
HBM HOLDINGS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.
Issue price:
--